Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q1 2024 vs. Q4 2023
How the institutions holding Alvotech changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 18 | 22 | +4 |
| Shares | 17.4M | 14.3M | −3.18M (−18.2%) |
| Value | $196.8M | $172.4M | −$24.4M (−12.4%) |
New holders (8)
Institutions that held Alvotech at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 250,123 | $3.06M | 0.01% |
| Northern Trust Corp | 121,257 | $1.48M | 0.00% |
| Occudo Quantitative Strategies LP | 24,120 | $294.7K | 0.05% |
| Cubist Systematic Strategies, LLC | 16,399 | $200.4K | 0.00% |
| Point72 Asset Management, L.P. | 11,700 | $143.0K | 0.00% |
| Amundi | 6,700 | $86.4K | 0.00% |
| JPMorgan Chase & Co | 301 | $3.68K | 0.00% |
| UBS Group AG | 2 | $24 | 0.00% |
Sold out (4)
Institutions that held Alvotech at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Temasek Holdings (Private) Ltd | 1,000,000 | $11.5M |
| Citadel Advisors LLC | 16,743 | $192.2K |
| Wolverine Asset Management LLC | 6,227 | $71.5K |
| Qube Research & Technologies Ltd | 16 | $184 |